Piper Sandler Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines (NASDAQ:RVMD) had its target price increased by analysts at Piper Sandler from $210.00 to $222.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler‘s price objective suggests a potential upside of 15.46% from the company’s current price.

RVMD has been the subject of a number of other reports. Stifel Nicolaus lifted their price objective on shares of Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Bank of America decreased their target price on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating on the stock in a research report on Friday, October 9th. Morgan Stanley started coverage on shares of Revolution Medicines in a report on Thursday, September 10th. They issued an “overweight” rating and a $255.00 price target for the company. William Blair initiated coverage on shares of Revolution Medicines in a report on Friday, October 16th. They issued an “outperform” rating for the company. Finally, The Goldman Sachs Group assumed coverage on Revolution Medicines in a research report on Thursday, September 24th. They issued a “buy” rating and a $267.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines has a consensus rating of “Moderate Buy” and an average target price of $263.15.

Revolution Medicines Price Performance

Shares of RVMD traded up $14.63 during mid-day trading on Thursday, hitting $192.28. 4,496,326 shares of the stock were exchanged, compared to its average volume of 1,940,895. The company has a market cap of $41.21 billion, a PE ratio of -21.11 and a beta of 1.44. Revolution Medicines has a 52-week low of $58.91 and a 52-week high of $224.31. The firm has a 50-day moving average of $196.88 and a two-hundred day moving average of $157.56. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same period last year, the business posted ($1.61) earnings per share. On average, equities analysts predict that Revolution Medicines will post -8.94 earnings per share for the current year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Mark Goldsmith sold 80,000 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the sale, the insider owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. This represents a 23.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Stephen Kelsey sold 92,531 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the completion of the sale, the insider owned 291,876 shares of the company’s stock, valued at $59,064,027.36. This trade represents a 24.07% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 290,991 shares of company stock valued at $59,422,765. Insiders own 7.60% of the company’s stock.

Institutional Trading of Revolution Medicines

Several institutional investors have recently added to or reduced their stakes in RVMD. Equitable Holdings Inc. bought a new position in Revolution Medicines in the 2nd quarter valued at $963,000. State of Wyoming purchased a new stake in Revolution Medicines in the second quarter worth $1,769,000. Handelsbanken Fonder AB lifted its position in shares of Revolution Medicines by 243.6% during the second quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock worth $39,755,000 after purchasing an additional 150,500 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Revolution Medicines during the second quarter worth $112,566,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Revolution Medicines during the second quarter worth $37,547,000. Institutional investors own 94.34% of the company’s stock.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.